Zacks Investment Research Upgrades Audentes Therapeutics (BOLD) to Hold
Zacks Investment Research upgraded shares of Audentes Therapeutics (NASDAQ:BOLD) from a sell rating to a hold rating in a research report released on Friday morning.
According to Zacks, “Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company’s product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. “
BOLD has been the subject of a number of other research reports. BidaskClub cut Audentes Therapeutics from a strong-buy rating to a buy rating in a research report on Wednesday, December 6th. ValuEngine cut Audentes Therapeutics from a hold rating to a sell rating in a research report on Friday, October 13th. William Blair reaffirmed a buy rating on shares of Audentes Therapeutics in a research report on Friday, January 5th. Raymond James Financial reaffirmed a hold rating on shares of Audentes Therapeutics in a research report on Thursday, January 4th. Finally, BMO Capital Markets started coverage on Audentes Therapeutics in a research report on Tuesday, December 5th. They issued an outperform rating and a $35.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Audentes Therapeutics has a consensus rating of Buy and a consensus price target of $35.00.
In other Audentes Therapeutics news, Director Louis G. Lange sold 18,000 shares of the business’s stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $30.88, for a total value of $555,840.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Mary Newman sold 10,000 shares of Audentes Therapeutics stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $26.84, for a total value of $268,400.00. The disclosure for this sale can be found here. Insiders sold 36,000 shares of company stock valued at $1,052,480 in the last ninety days. Insiders own 47.30% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in shares of Audentes Therapeutics in the third quarter worth about $143,000. Teacher Retirement System of Texas bought a new position in shares of Audentes Therapeutics in the fourth quarter worth about $208,000. Nationwide Fund Advisors increased its stake in shares of Audentes Therapeutics by 288.9% in the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 6,384 shares during the period. Trexquant Investment LP bought a new position in shares of Audentes Therapeutics in the third quarter worth about $295,000. Finally, Virtus Fund Advisers LLC bought a new position in shares of Audentes Therapeutics in the fourth quarter worth about $372,000. Institutional investors and hedge funds own 64.94% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2018/02/12/zacks-investment-research-upgrades-audentes-therapeutics-bold-to-hold.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.